Prolium Bioscience, Inc.

Prolium Bioscience, Inc. is a US-based biotechnology company focused on developing innovative therapies for severe autoimmune diseases, particularly through its leading product, PRO-203. Founded in 2025 and headquartered in New York, US, Prolium Bioscience, Inc. specializes in creating advanced therapeutics for autoimmune disorders.

The company raised USD 50 mn in its Series A funding round, led by RTW Investments, with the most recent deal occurring on March 3, 2026. The founder's history is not detailed. Prolium Bioscience specializes in developing innovative therapies aimed at treating severe autoimmune diseases, focusing on its flagship product, PRO-203, a CD20xCD3 T-Cell Engager. This advanced therapeutic engages T-cells to target B-cells, modulating the immune response in patients.

The company serves a diverse client base including healthcare providers and research institutions, targeting markets in North America and Europe where autoimmune disorders are prevalent. Prolium prioritizes patient needs and aims to improve health outcomes through scientific advancements. Prolium Bioscience's revenue model is structured around the commercialization of its therapeutic products, particularly through partnerships with healthcare providers and research institutions. Healthcare organizations procure PRO-203 for clinical use, reflecting the complexity of its biopharmaceutical innovations.

Prolium seeks collaborations to enhance distribution channels, ensuring effective delivery of its therapies. In March 2026, Prolium Bioscience, Inc. raised USD 50 mn in Series A funding, which will be utilized to run clinical studies of PRO-203 in systemic sclerosis and other severe autoimmune diseases. The company is focused on expanding its product offerings and plans to enter new markets in Europe and North America by 2027.

This funding will support the development and testing of its therapies to meet the growing needs for effective treatments in these regions.